参考文献/References:
[1] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2020概要[J]. 中国循环杂志，2021，36(6): 521-545.
[2] 周茜洋，唐春香，张龙江，等. 残余炎性心血管风险的研究进展[J]. 医学研究生学报，2020，33(7): 760-764.
[3] Mazur M, Zielińska A, Grzybowski M M, et al. Chitinases and Chitinase-like proteins as therapeutic targets in inflammatory diseases, with a special focus on inflammatory bowel diseases[J]. International Journal of Molecular Sciences, 2021, 22(13): 6966.
[4] Liu X, Zhang J, Zhu K Y. Chitin in arthropods: biosynthesis, mModification, and metabolism[J]. Advances in Experimental Medicine and Biology, 2019, 1142: 169-207.
[5] 邢玉，郭靖涛，盖鲁粤. 人软骨糖蛋白-39与冠心病关系的研究进展[J]. 解放军医学院学报，2017，38(1): 92-95.
[6] Rathcke C N, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis[J]. Inflammation Research, 2006, 55(6): 221-227.
[7] 蔡琼，韩辉武，彭珊珊，等. 心血管病住院患者代谢综合征与ASCVD的风险因素分析[J]. 中国医药导报，2020，17(14): 57-60.
[8] Akbo? M K, Yal?#305n R, ?hinarslan A, et al. Increased serum YKL-40 level is associated with the presence and severity of metabolic syndrome[J]. The Anatolian Journal of Cardiology, 2016, 16(12): 953-958.
[9] 于叶叶，石鑫，谭丽艳，等. 代谢综合征患者血清YKL-40水平变化及意义[J]. 黑龙江医药科学，2018，41(1): 32-34.
[10] 陈迪芳，林金秀. 代谢综合征患者人软骨糖蛋白-3浓度变化及与危险因素个数的关系[J]. 中国循环杂志，2014，29(3): 201-205.
[11] 聂秋平，刘美霞. 肥胖与心血管疾病相关性的研究进展[J]. 国际心血管病杂志，2018，45(1): 27-30.
[12] Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Peripheral mononuclear blood cells contribute to the obesity-associated inflammatory state independently of glycemic status: involvement of the novel proinflammatory adipokines chemerin, chitinase-3-like protein 1, lipocalin-2 and osteopontin[J]. Genes and Nutrition, 2015, 10(3): 460.
[13] Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Increased circulating and visceral adipose tissue expression levels of YKL-40 in obesity-associated type 2 diabetes are related to inflammation: impact of conventional weight loss and gastric bypass[J]. Journal of Clinical Endocrinology and Metabolism, 2011, 96(1): 200-209.
[14] Hempen M, Kopp H P, Elhenicky M, et al. YKL-40 is elevated in morbidly obese patients and declines after weight loss[J]. Obesity Surgery, 2009, 19(11): 1557-1563.
[15] 钮利娟. 血清人软骨糖蛋白-39（YKL-40）与2型糖尿病的相关性研究[D]. 苏州，苏州大学，2013.
[16] Lee H, Kang R, Jee S H, et al. A promoter polymorphism-2122 C>T of CHI3L1 is associated with serum low density lipoprotein cholesterol level in Korean subjects[J]. Clinical Biochemistry, 2010, 43(15): 1195-1200.
[17] Thomsen S B, Rathcke C N, Skaaby T, et al. The Association between genetic variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and the lipid profile in a Danish population[J]. PLoS One, 2012, 7(10): e47094.
[18] Kjaergaard A D, Johansen J S, Bojesen S E, et al. Elevated plasma YKL-40, lipids and lipoproteins, and ischemic vascular disease in the general population published correction appears in stroke[J]. Stroke, 2015, 46(2): 329-335.
[19] 张纯燕，王冬，张慎和. 2型糖尿病合并冠心病冠状动脉特点及危险因素分析[J]. 解放军医药杂志，2019，31(4): 64-66.
[20] Smekal A, Vaclavik J. Adipokines and cardiovascular disease: a comprehensive review[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2017, 161(1): 31-40.
[21] 刘海蔚，陈道雄，陈开宁，等. 肥胖2型糖尿病患者血清几丁质酶3样蛋白1水平与胰岛素抵抗指数及糖化血红蛋白关系的研究[J]. 中国糖尿病杂志，2019，27(12): 900-902.
[22] 董丽，杨丽霞，郭海霞，等. 血清胆红素、YKL-40、HMGB-1对糖尿病合并冠心病患者的临床意义[J]. 现代生物医学进展，2019，19(20): 3973-3976，3981.
[23] Rathcke C N, Johansen J S, Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance[J]. Inflammation Research, 2006, 55(2): 53-59.
[24] Luo W, Zhang L, Sheng L, et al. Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis[J]. Diabetology and Metabolic Syndrome, 2021, 13(1): 6.
[25] Persson F, Rathcke C N, Gall M A, et al. High YKL-40 levels predict mortality in patients with type 2 diabetes[J]. Diabetes Research and Clinical Practice, 2012, 96(1): 84-89.
[26] 周言. 原发性高血压靶器官损害YKL-40、PTX-3的相关性研究[D]. 衡阳: 南华大学，2014.
[27] 赵萌萌. 人软骨糖蛋白39与原发性高血压早期心血管损伤的相关性研究[D]. 济南: 山东大学，2018.
[28] 马伟红. 原发性高血压患者人软骨糖蛋白39（YKL-40）与动脉粥样硬化的相关性研究[D]. 济南: 山东大学，2011.
[29] Xu T, Zhong C, Wang A, et al. YKL-40 level and hypertension incidence: a population-based nested case-control study in China[J]. Journal of the American Heart Association, 2016, 5(11): e004534.
[30] Xu T, Zhong C, Wang A, et al. YKL-40 is a novel biomarker for predicting hypertension incidence among prehypertensive subjects: a population-based nested case-control study in China[J]. Clinica Chimica Acta, 2017, 472: 146-150.
[31] ?tin M, Erdo?n T, K??#351 T, et al. Elevated serum YKL40 level is a predictor of MACE during the long-term follow up in hypertensive patients[J]. Clinical and Experimental Hypertension, 2020, 42(3): 271-274.
[32] Khambhati J, Engels M, Allard-Ratick M, et al. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: promise and possibilities[J]. Atherosclerosis, 2018, 276: 1-9.
[33] Tall A R. Plasma high density lipoproteins: therapeutic targeting and links to atherogenic inflammation[J]. Atherosclerosis, 2018, 276: 39-43.
[34] Ruscica M, Ferri N, Macchi C, et al. Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes[J]. Annals of Medicine 2018, 50(6): 461-484.
[35] Montarello N J, Nguyen M T, Wong D T L, et al. Inflammation in coronary atherosclerosis and its therapeutic implications[J]. Cardiovascular Drugs and Therapy, 2020, 11: 10.
[36] Boot R G, van Achterberg T A, van Aken B E, et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages[J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19(3): 687-694.
[37] Michelsen A E, Rathcke C N, Skjelland M, et al. Increased YKL-40 expression in patients with carotid atherosclerosis [J]. Atherosclerosis, 2010, 211(2): 589-595.
[38] Tan Y, Ji X, Mo Z, et al. Serum YKL-40 positively correlates with MMP-9 and CRP in patients with acute ST segment elevation myocardial infarction following emergency treatment[J]. Medicine, 2019, 98(47): e17950.
[39] 张帆，刘俊明. YKL-40在冠状动脉粥样硬化性心脏病的致病机制研究动态[J]. 心肺血管病杂志，2013，32(2): 227-229.
[40] Rathcke C N, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis[J]. Inflammation Research, 2006, 55(6): 221-227.
[41] 刘欣，牛慧敏，张明明，等. 血清YKL-40蛋白水平与颈动脉斑块内新生血管形成的关系[J]. 卒中与神经疾病，2017，24(5): 398-401，415.
[42] 王超. YKL-40，hs-CRP及HCY在冠心病患者的表达水平分析[D]. 张家口: 河北北方学院，2018.
[43] 李珍珍，李倩，荆晶，等. 几丁质酶-3样蛋白-1与冠心病患者冠脉病变狭窄程度的相关性分析[J]. 解放军医学院学报，2018，39(10): 853-856.
[44] Jin Y, Cao J N, Wang C X, et al. High serum YKL-40 level positively correlates with coronary artery disease[J]. Biomarkers in Medicine, 2017, 11(2): 133-139.
[45] ?iborski K, Kuliczkowski W, Karolko B, et al. Plasma YKL-40 levels correlate with the severity of coronary atherosclerosis assessed with the SYNTAX score[J]. Polish Archives of Internal Medicine, 2018, 128(11): 644-648.
[46] 田婷婷，周明艳，伦立民. AMI患者血清甲壳质酶蛋白-40水平与心室重构的相关性分析[J]. 国际检验医学杂志，2018，39(21): 2633-2636.
[47] 周辰旭. 急性ST段抬高型心肌梗死患者血清YKL-40的变化及意义[D]. 大连: 大连医科大学，2019.
[48] Schroder J, Jakobsen J C, Winkel P, et al. Prognosis and reclassification by YKL-40 in stable coronary artery disease[J]. Journal of the American Heart Association, 2020, 9(5): e014634.
[49] 白银龙，贾永平，郭贝贝. 冠心病病人PCI术后血清YKL-40及hs-CRP变化与预后的相关性研究[J]. 中西医结合心脑血管病杂志，2017，15(16): 1999-2002.
[50] Yang L, Dong H, Lu H, et al. Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction[J]. Medicine, 2019, 98(12): e14920.
[51] Harada M, Nattel S. Implications of inflammation and fibrosis in atrial fibrillation pathophysiology[J]. Journal of Cardiac Electrophysiology. 2021, 13(1): 25-35.
[52] 王山山，梁兆光. 炎症反应与心房颤动的关系[J]. 心血管病学进展，2019，40(5): 770-773.
[53] 孙静美，尹德春，曲秀芬. 炎症信号与心房颤动[J]. 心血管病学进展，2020，41(1): 31-34.
[54] ichelakakis N, Neroutsos G J, Perpinia A S, et al. Chitinase-3-like protein-1 (YKL-40) before and after therapy in supraventricular arrhythmias[J]. Journal of Cardiovascular Medicine, 2017, 18(9): 650-654.
[55] Henningsen K M, Therkelsen S K, Johansen J S, et al. Plasma YKL-40, a new biomarker for atrial fibrillation [J]. Europace, 2009, 11(8): 1032-1036.
[56] Wang Q, Shen H, Min J, et al. YKL-40 is highly expressed in the epicardial adipose tissue of patients with atrial fibrillation and associated with atrial fibrosis[J]. Journal of Translational Medicine, 2018, 16(1): 229.
[57] Marott S C, Benn M, Johansen J S, et al. YKL-40 levels and atrial fibrillation in the general population[J]. International Journal of Cardiology, 2013, 167(4): 1354-1359.
[58] Henningsen K M, Nilsson B, Johansen J S, et al. Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation[J]. Inflammation Research, 2010, 59(6): 463-469.
[59] Bilim O, Takeishi Y, Kitahara T, et al. Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure[J]. Journal of Cardiac Failure, 2010, 16(11): 873-879.
[60] 卓裕丰，程颖，解强，等. 慢性心力衰竭与几丁质酶-3样蛋白-1的相关性探讨[J]. 广州医学院学报，2013，41(1): 7-9.
[61] Rathcke C N, Kistorp C, Raymond I, et al. Plasma YKL-40 levels are elevated in patients with chronic heart failure[J]. Scandinavian Cardiovascular Journal, 2010, 44(2): 92-99.
[62] Harutyunyan M, Christiansen M, Johansen J S, et al. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure[J]. Immunobiology, 2012, 217(6): 652-656.